Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALKBH1 | Q13686 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19434598 | 0.88 | LMNA (0.42) | EGLN1L3MBTL1HDAC3HDAC4HDAC1 | |
| SCHEMBL25122939 | 0.87 | EGLN1 (0.51) | EGLN1L3MBTL1ALKBH1CYP4F2CYP4A11 | |
| SCHEMBL17869288 | 0.86 | EGLN1 (0.47) | EGLN1L3MBTL1ALKBH1HDAC3HDAC4 | |
| SCHEMBL4236522 | 0.83 | ALDH1A1 (0.44) | EGLN1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4237888 | 0.81 | KLKB1 (0.46) | EGLN1NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL27032021 | 0.80 | SMN1; SMN2 (0.45) | NPC1TP53RAB9ASMN1; SMN2HDAC3 | |
| SCHEMBL838950 | 0.79 | L3MBTL1 (0.61) | EGLN1L3MBTL1ALKBH1HDAC3HDAC4 | |
| SCHEMBL25122835 | 0.77 | L3MBTL1 (0.52) | EGLN1L3MBTL1ALKBH1HPGDSALKBH2 | |
| SCHEMBL25122875 | 0.77 | L3MBTL1 (0.52) | EGLN1L3MBTL1ALKBH1HPGDSALKBH2 | |
| SCHEMBL25122913 | 0.77 | L3MBTL1 (0.52) | EGLN1L3MBTL1ALKBH1HPGDSALKBH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12097261-B2 | CDK2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097261-B2 | CDK2 degraders and uses thereof | CDK2, CDK20, CDK1 | EGLN1 3242/4885L3MBTL1 2534/4885ALKBH1 3368/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | EGLN1 3242/4885L3MBTL1 2534/4885ALKBH1 3368/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | EGLN1 3242/4885L3MBTL1 2534/4885ALKBH1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.